Analysis of placebo-treated patients in the Phase 2 OCEAN(a)-DOSE trial of olpasiran in patients with Lp(a) concentration >150 nmol/L and established atherosclerotic cardiovascular disease (ASCVD) has shown notable intraindividual variability in serial Lp(a) concentration during follow-up.
